Shuttle Pharmaceuticals Inc logo

Shuttle Pharmaceuticals Inc(SHPH)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
WEAK BUY
BUY for 31 days
PROFIT SINCE LAST BUY
+8.63% ▲
LAST CLOSE
$4.53
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SHPH

11/13/2026: SHPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Shuttle Pharmaceuticals is a clinical-stage biotechnology firm focused on developing small-molecule radiation sensitizers to improve cancer patient outcomes. The company's primary strength lies in its specialized focus on addressing unmet needs in radio-oncology, with its lead candidate, Ropidoxuridine, representing the key investment story. However, as an early-stage company without commercial products, it faces high execution, regulatory, and financial risks. The stock is best suited for speculative, risk-tolerant investors who understand that success is contingent upon positive clinical data. Key developments to monitor include ongoing clinical trial results and any potential strategic partnerships that could provide necessary validation and capital.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThis is a high-risk growth opportunity tied to binary clinical trial outcomes.
Momentum investorWeak fitMomentum is generally tied to positive trial data catalysts rather than sustained market trends.
Value investorWeak fitThe company currently lacks revenue and earnings, making traditional value metrics inapplicable.
Dividend investorWeak fitThere is no dividend income and capital is reinvested into R&D.
Low-risk investorWeak fitClinical-stage biotechnology carries high volatility and risk of capital loss.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stocks are susceptible to sharp price swings based on trial news.
Valuation riskHighValuations are highly speculative as they depend on future, unproven clinical success.
Competition risk (Oncology market)HighThe company competes against much larger firms with superior financial resources.
Business qualityMedium / highThe business is early-stage with limited tangible assets or commercial products.
Dividend incomeLow / noneNo dividend payments are expected for the foreseeable future.
Execution riskHighThe company must navigate complex regulatory and clinical hurdles to achieve commercialization.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 21.58M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 38.7K shares
Beta 1.02
52 Weeks Range 2.58 - 27.30
Updated Date 11/14/2026
52 Weeks Range 2.58 - 27.30
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -16.87

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -39.05%
Avg. Invested days 16
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SHPH receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft company fundamentals, and soft analyst coverage.

Company Fundamentals

★★★★★
SHPH has soft overall fundamentals (2 stars), with moderate financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-28.2%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
SHPH's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
SHPH's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-28.2%, negative) and free-cash-flow growth (-29.4%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 1.5% (soft) and 99.8% of outstanding shares are publicly tradable (strong). Insider ownership is only 0.84%, which materially reduces the ownership score.

Top 5 Institutional Investors

HRT FINANCIAL LLC 1.65%
Citadel Advisors Llc 0.51%
Barclays PLC 0.02%
Tower Research Capital LLC 0.01%
Wall Street Access Asset Management, LLC 0.00%

Unit Economics (Per $1K Revenue)

★★★★★
SHPH generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
SHPH has a liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Small / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical DevelopmentAdvancing drug candidates through FDA trials for future commercialization.The company is currently burning cash to develop drugs and does not yet earn regular revenue.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 22.78M
Price to Sales(TTM) -
Enterprise Value 22.78M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.67
Shares Outstanding 4.76M
Shares Floating 4.76M
Shares Outstanding 4.76M
Shares Floating 4.76M
Percent Insiders 0.84
Percent Institutions 1.48

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.